Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.